# IXICO appoints Chief Commercial Officer to accelerate business development activity and broaden US footprint 5 Feb 26 news # IXICO appoints Chief Commercial Officer to accelerate business development activity and broaden US footprint [ ](https://x.com/intent/tweet?url=https://ixico.com/news-and-resources/news/ixico-appoints-chief-commercial-officer-to-accelerate-business-development-activity-and-broaden-us-footprint/) [ ](https://bsky.app/intent/compose?text=https://ixico.com/news-and-resources/news/ixico-appoints-chief-commercial-officer-to-accelerate-business-development-activity-and-broaden-us-footprint/) [ ](https://www.facebook.com/sharer/sharer.php?u=https://ixico.com/news-and-resources/news/ixico-appoints-chief-commercial-officer-to-accelerate-business-development-activity-and-broaden-us-footprint/) [ ](https://www.linkedin.com/shareArticle?mini=true&url=https://ixico.com/news-and-resources/news/ixico-appoints-chief-commercial-officer-to-accelerate-business-development-activity-and-broaden-us-footprint/) **Tanya Voloshen, CCO joins IXICO as a member of the Senior Leadership Team with deep commercial and executive leadership experience in the neuroimaging market** 05 February 2026, IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced that it has appointed Tanya Voloshen as Chief Commercial Officer (CCO) based in Boston, Massachusetts (USA). Tanya joins IXICO from Perceptive Inc. a global contract research organisation (CRO) where she held the role as SVP Commercial.  Prior to joining Perceptive, Tanya held senior commercial leadership roles for international clinical trial and medical technology companies with a focus on neuroscience and medical imaging including Clario (now part of Thermo Fisher Scientific), QMENTA and ConcertAI. Tanya started her career in the pharmaceutical industry working for Johnson & Johnson and Sanofi. **Bram Goorden, Chief Executive Officer of IXICO, commented**: *“I am very pleased to welcome Tanya to IXICO as CCO, a newly appointed position in the senior leadership team that reflects a firm and continued commitment to strengthen our commercial capabilities and accelerate growth. Based in Boston, Tanya brings strong commercial leadership experience, established customer relationships and an excellent understanding of the critical contribution that IXICO’s technology platform can make in the clinical imaging market.”* [ Back to News ](/news-and-resources/news/) ### Recents ![IXICO announces £2.7 million Phase 3 contract win in Huntington’s disease](/assets/blog-images/HD-contract-win__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp) 2 Nov 26 news [IXICO announces £2.7 million Phase 3 contract win in Huntington’s disease](/news-and-resources/news/2-7-million-phase-3-contract-win-in-huntingtons-disease/) [IXICO presents research on novel methods to reduce unwanted variability in Huntington’s disease biomarker data ](/news-and-resources/news/ixico-presents-research-on-novel-methods-to-reduce-unwanted-variability-in-huntingtons-disease-biomarker-data/) [IXICO announces two contracts in Alzheimer's disease worth £1.5 million](/news-and-resources/news/ixico-announces-two-contracts-in-alzheimers-disease-worth-1-5-million/) [IXICO announces 28% expected revenue growth for FY26](/news-and-resources/news/ixico-trading-update-for-year-ending-30-september-2026/) [IXICO to present advancements in neuroimaging for Parkinson’s disease at European radiology conference ](/news-and-resources/news/ixico-to-present-advancements-in-neuroimaging-for-parkinsons-disease/) ### Library [November 2026](/news-and-resources/news/archive/2026/11/) [October 2026](/news-and-resources/news/archive/2026/10/) [September 2026](/news-and-resources/news/archive/2026/09/) [July 2026](/news-and-resources/news/archive/2026/07/) [June 2026](/news-and-resources/news/archive/2026/06/) [May 2026](/news-and-resources/news/archive/2026/05/) [April 2026](/news-and-resources/news/archive/2026/04/) [March 2026](/news-and-resources/news/archive/2026/03/) [February 2026](/news-and-resources/news/archive/2026/02/) [January 2026](/news-and-resources/news/archive/2026/01/) [2025](/news-and-resources/news/archive/2025/) [2024](/news-and-resources/news/archive/2024/) [2023](/news-and-resources/news/archive/2023/) [2022](/news-and-resources/news/archive/2022/) [2021](/news-and-resources/news/archive/2021/) [2020](/news-and-resources/news/archive/2020/) [2019](/news-and-resources/news/archive/2019/)